Lota S. Zoth
CIK 1278219 · CHIEF SCIENTIFIC OFFICER · last filed 2026-06-17
Lota S. Zoth is a CHIEF SCIENTIFIC OFFICER who has filed 66 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for ENGNW, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$84.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $90.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$90.4K
11
66
-$84.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ENGNW | Director | — | $0.36 | — | $0 | 4 | 2026-06-17 |
| INO | Director | 8,726 | $1.03 | $9.0K | -$37.8K | 15 | 2026-05-21 |
| FFIN | Director | 2,142 | $35.21 | $75.4K | $0 | 1 | 2026-05-05 |
| 89bio, Inc. (ETNB) Delisted | Director | — | $14.84 | — | $0 | 7 | 2025-10-30 |
| LUMOS PHARMA, INC. (LUMO) Delisted | Director | 0 | $4.34 | $0 | $0 | 6 | 2024-12-13 |
| ZYME | Director | — | $22.61 | — | $0 | 4 | 2022-12-23 |
| LUMOS PHARMA, INC. (NLNK) Delisted | Director | 1,112 | — | — | $0 | 11 | 2020-01-06 |
| Spark Therapeutics, Inc. (ONCE) Delisted | CHIEF SCIENTIFIC OFFICER | 0 | — | — | $0 | 6 | 2019-12-17 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | — | — | — | $0 | 6 | 2017-07-18 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 2 | 2015-05-08 |
| MEDI | SVP, Chief Financial Officer | 178 | $33.42 | $5.9K | -$46.2K | 3 | 2007-06-19 |
Recent Filings
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | ENGNW | Grant (A) | — | $0 | EDGAR |
| 2026-05-21 | INO | Grant (A) | — | $0 | EDGAR |
| 2026-05-05 | FFIN | Grant (A) | +2,142 | $0 | EDGAR |
| 2025-10-30 | 89bio, Inc. (ETNB) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-16 | ENGNW | Grant (A) | — | $0 | EDGAR |
| 2025-05-21 | INO | Exer (M) | +2,167 | $0 | EDGAR |
| 2025-02-05 | 89bio, Inc. (ETNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-13 | LUMOS PHARMA, INC. (LUMO) Delisted | Disp (D) | −2,187 | $0 | EDGAR |
| 2024-06-18 | ENGNW | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | LUMOS PHARMA, INC. (LUMO) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.